180 results about "Immunologic Stimulation" patented technology

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

To provide a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate, and a production intermediate thereof, and to provide methods for producing a cyclic dinucleotide-linker and antibody-immunostimulator conjugate using the production method.SOLUTION: The present invention relates to a method that makes it possible to produce, in large amounts and with high yield, a cyclic dinucleotide derivative having a desired steric configuration, by using an optically active phosphitylation agent twice, during coupling and cyclization.SELECTED DRAWING: None

The present invention relates to a bispecific antibody that specifically binds to VISTA and MSLN, and uses thereof. The bispecific antibody exhibits significant immuno-oncological activity and ADCC activity compared to a monospecific antibody, degrades target proteins through internalization activity, and possesses tumor-targeting ability, and thus can be advantageously used for the prevention or treatment of various cancers.

The present invention relates to a composition for enhancing immunity, containing, as an active ingredient, a polysaccharide enzyme-treated product derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified polysaccharide fraction thereof. The composition for enhancing immunity according to the present invention, comprising the polysaccharide enzyme-treated product of the mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora or the novel purified polysaccharide fraction thereof, is composed of specific types and contents of sugars and significantly increases the activity of macrophages, splenocytes, and NK cells upon application thereto, thereby being applicable as an immunopotentiator or a composition for enhancing immunity.

The present invention relates to the technical field of biomedicine, and in particular to an adjuvant composition, a respiratory syncytial virus (RSV) vaccine composition, and a use thereof. An aluminum adjuvant and a CpG ODN adjuvant are combined in proportion to form an adjuvant composition. An RSV vaccine composition comprising the adjuvant composition has better immunostimulatory activity, can enable early induction of a high humoral immune response, can maintain a strong cellular immune response for a long time, can produce an immune response comparable to that of a licensed vaccine Arexvy, and is a safe, effective and promising human RSV candidate vaccine.

The present invention relates to the field of vaccines, and in particular to a novel adjuvant polypeptide sequence and a use thereof. The adjuvant polypeptide sequence provided by the present invention comprises amino acid sequences of tetanus toxoid epitopes P2 and P16 and further comprises amino acid sequences of P30 and / or PX. The adjuvant polypeptide sequence aims to expand the coverage population of immune responses by increasing epitope diversity. In addition, the present invention uses an LNP (lipid nanoparticle) delivery system to introduce an mRNA encoding an adjuvant polypeptide and an initial antigen protein into a human body, thereby improving the immunostimulatory ability of the initial antigen. The adjuvant polypeptide sequence provided by the present invention and the initial antigen sequence are preferably fused, thereby simplifying the composition of mRNA in a nucleic acid vaccine and reducing the complexity of vaccine preparation.

To provide an immunostimulating composition.SOLUTION: An immunostimulating composition comprises, as an active ingredient, a bacterium that is phagocytosed by plasmacytoid dendritic cells (pDC) at or above a predetermined level.SELECTED DRAWING: None

What is described is a peptide for use in the reduction of side-effects in form of immunostimulatory reactions / effects which occur with gene therapy, wherein the peptide is coupled to a nucleic acid molecule used in gene therapy. Furthermore, such a peptide is described for use in the reduction of side-effects in form of immunostimulatory reactions / effects which occur with gene therapy, wherein the peptide is coupled to a nucleic acid molecule used in gene therapy, wherein the immunostimulatory reactions / effects are induced by activation of IFIT1 / 2, IRF9, TLR3, TLR7, TLR8 or PKR.

The invention provides a preparation method and application of a nitrogen-containing heterocyclic micromolecule modified polyethyleneimine polymer derivative. Compared with a polyethyleneimine polymer, the nitrogen heterocyclic ring micromolecule modified polyethyleneimine polymer derivative provided by the invention has immunostimulatory activity. Besides, the polymer derivative material provided by the invention can be simply mixed with a protein antigen to form nanoparticles, so that efficient loading of the protein antigen is realized, the delivery efficiency of the protein antigen to lymph nodes is improved, and the polymer derivative material can be used for preparing a novel nano vaccine preparation.

Disclosed is a immunostimulatory composition comprising a bacterium having an immunostimulatory ability, and one or more compounds selected from the group consisting of vitamins having an immunostimulatory ability-enhancing effect on the bacterium, and vitamin-like substances.

The present invention provides an siRNA that inhibits angiopoietin-like 4 (ANGPTL4) gene expression, wherein the siRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises at least 17 continuous nucleotides that differ by no more than 4 nucleotides from the nucleotide sequences as shown in SEQ ID NO: 143, and the antisense strand is 17 to 30 nucleotides in length; the sense strand is 17 to 30 nucleotides in length and is at least partially complementary to the antisense strand. The siRNA, siRNA conjugate, and pharmaceutical composition provided in the present invention exhibit good stability, ANGPLT4 gene inhibitory activity, and immunostimulation, and can significantly reduce ANGPTL4 protein concentrations at the animal level.

A SARS-CoV-2 immunotherapeutic targeted fusion protein regimen or vaccine in which the extracellular domain (ecd) of the CD40L immunostimulatory protein, is attached individually to mRNA encoding a Selected Fragment of the Spike Protein (SFSP), representing a different functional feature and a different domain or domain region, or both of the Spike Protein, to generate 7 distinct SFSP / ecdCD40L translation units, each translation unit being converted into a SFSP / ecdCD40L fusion protein regimen or vaccine and all combined into a single fusion protein mixture or composition for injection, preferably inter-muscularly (im). Each fragment or peptide is designed to activate a humoral and cellular immune response to a different SFSP. Each SFSP fragment or peptide, as a vaccine strategy for the SARS-CoV-2 virus, has the capability to suppress the emergence of immunological escape mutants. The fusion protein mixture or composition of multiple fragments or peptides could be incorporated in any one of several delivery platforms such as an adenoviral expression vector or an mRNA platform.

The present invention provides an immunologic stimulant which contains Lactobacillus helveticus, and wherein the Lactobacillus helveticus has three functions: the activation of dendritic cell-like cells, the induction of the production of immunoglobulin A (IgA), and the induction of the production of interleukin-12 (IL-12).

Devices and methods for obtaining immunostimulatory antigen presenting cells. The present invention relates to methods for producing immunostimulatory antigen presenting cells. The invention also relates to the use of such cells for treating a patient suffering from a hyperproliferative disease, such as cancer.

The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.

This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.

To provide a method for identifying a therapy recommendation for a subject exhibiting dysregulated host response.SOLUTION: A classification of the subject of subtype A, subtype B, or subtype C is obtained. The therapy recommendation for the subject is identified based at least in part on the classification. Responsive to the classification of the subject comprising the subtype A, the therapy recommendation can be no immunosuppressive therapy. Responsive to the classification of the subject comprising the subtype B, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, blocking of complement activity therapy, and / or anti-inflammatory therapy. Responsive to the classification of the subject comprising the subtype C, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, modulators of coagulation therapy, and / or modulators of vascular permeability therapy.SELECTED DRAWING: Figure 1A

Disclosed is an immunostimulatory composition comprising a bacterium having immunostimulatory ability and a plant extract having an effect of enhancing the immunostimulatory ability of the bacterium.

The invention belongs to the technical field of biology, and particularly relates to a new target spot, a method and application for inducing a helicobacter pylori mucosal immune response reaction. Aiming at the problems of poor immune effect, safety risk and the like due to the fact that the existing helicobacter pylori mucosal immune response is induced mainly through oral administration or nasal drop treatment, the invention provides a new target spot for inducing the helicobacter pylori mucosal immune response, and the target spot is positioned at the oropharynx of a mouse. The invention further provides a novel method for inducing the helicobacter pylori mucosal immune response. The method comprises the step of performing immunostimulation on the oropharyngeal mucosa of a mouse by adopting the helicobacter pylori antigen. The invention further provides application of the novel target spot, and the novel target spot is used for developing helicobacter pylori mucosal immune vaccines. The target spot can induce humoral immunity and mucosal immunity response, can efficiently inhibit helicobacter pylori colonization in the stomach of a mouse, and reduces the infection rate. The vaccine based on the target spot has the advantages of being convenient to use and remarkable in effect, and a reliable strategy is provided for prevention and treatment of helicobacter pylori.

A pharmaceutical composition comprising: i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them; ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide. Use of the pharmaceutical composition in the preparation of a medicament for preventing and / or treating a varicella-zoster virus infection and / or a varicella-zoster virus mediated disease. The pharmaceutical composition achieves an unexpected technical effect and can mediate a stronger immune response.

Disclosed is an immunostimulatory composition containing, as an active ingredient, bacteria which bond to BDCA2 and / or bacteria which are phagocytosed by plasmacytoid dendritic cells (pDCs) to at least a prescribed degree.

The present disclosure provides engineered mesenchymal stem cells (MSCs), a pharmaceutical composition containing the same, and use thereof in the manufacture of a medicament for treating cancer. The mesenchymal stem cells (MSCs) comprise an introduced NQO1 protein-coding sequence and / or an introduced hypoxia response element (HRE), and a nucleic acid encoding one or more immunostimulatory cytokines.

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and / or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

An immunotherapeutic mRNA vaccine comprises a first translation unit comprising a secretable first fusion protein comprising a co-stimulatory molecule fused to a first TAA, adapted to generate a first TAA specific adaptive immune response by way of a first immunostimulatory pathway. The immunotherapeutic mRNA vaccine also comprises a second translation unit comprising a non-secretable second fusion protein comprising an identical co-stimulatory molecule fused to a second TAA identical to the first TAA, adapted to generate a second TAA specific adaptive immune response by way of a second immunostimulatory pathway, whereby the at least two immune response interact at one or more locations downstream to amplify the first TAA specific adaptive immune response.

Methods and compositions for the treatment of viral infections, such as HIV infection, are disclosed herein. In certain embodiments, a molecular conjugate comprising a viral capture domain and an immunostimulant molecule is provided.

To provide an immunostimulatory bacterial delivery platform and its use for delivery of therapeutic products.SOLUTION: Provided are immunostimulatory bacteria containing genomic modifications and plasmids encoding one or more therapeutic products, e.g., an anti-cancer therapeutic agent or a related treatment. The genome modification results in the immunostimulatory bacteria accumulating in tumor resident immune cells within the tumor microenvironment, where the encoded therapeutic product is expressed. The immunostimulatory bacteria provided herein encode one or more of the complementation products that stimulate, induce or result in a robust anti-cancer response in a subject.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;